Literature DB >> 28585559

Prostate cancer: Escaping enzalutamide: Malat1 contributes to resistance.

Louise Stone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28585559     DOI： 10.1038/nrurol.2017.91

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.

Authors:  Ronghao Wang; Yin Sun; Lei Li; Yuanjie Niu; Wanying Lin; Changyi Lin; Emmanuel S Antonarakis; Jun Luo; Shuyuan Yeh; Chawnshang Chang
Journal:  Eur Urol       Date:  2017-05-18       Impact factor: 20.096
  1 in total
  3 in total

1.  CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.

Authors:  Xi Chen; Yechen Wu; Xinan Wang; Chengdang Xu; Licheng Wang; Jingang Jian; Denglong Wu; Gang Wu
Journal:  Eur J Med Res       Date:  2022-07-02       Impact factor: 4.981

2.  MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice.

Authors:  Maximilian Marhold; Simon Udovica; Thais Topakian; Peter Horak; Reinhard Horvat; Erwin Tomasich; Gerwin Heller; Michael Krainer
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

Review 3.  LncRNA as a multifunctional regulator in cancer multi-drug resistance.

Authors:  Jiaying He; Shaomi Zhu; Xin Liang; Qinxiu Zhang; Xiaohong Luo; Chi Liu; Linjiang Song
Journal:  Mol Biol Rep       Date:  2021-07-31       Impact factor: 2.316
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.